Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Marksans Pharma Limited (NSE: MARKSANS), ISIN INE750C01026 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
MARKSANS last traded at ₹347.45 (+4.40%), with a 52-week range of ₹156.00 to ₹349.70 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 43.87%, FIIs 17.47%, DIIs 6.19%, mutual funds 4.36%.
EquiSense Score (ECS): 83/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.